middle.news
Radiopharm Advances Multiple Trials and Secures $8M Placement Amid Nasdaq Debut
11:22am on Thursday 30th of January, 2025 AEDT
•
Healthcare
Read Story
Radiopharm Advances Multiple Trials and Secures $8M Placement Amid Nasdaq Debut
11:22am on Thursday 30th of January, 2025 AEDT
Key Points
Ethics approvals granted for Phase 1 RAD202 and expanded RAD204 trials
Preclinical completion of RAD402 with human trials planned for H2 2025
Strategic partnerships with AtomVie and Lantheus, including co-development and manufacturing deals
A$8 million placement by Lantheus increases its stake to 12.16%
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Radiopharm Theranostics (ASX:RAD)
OPEN ARTICLE